Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Organon & Co. Common Stock — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.7 (market cap $753.07M), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is far larger — about 4.8× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 57 Days and Organon & Co. Common Stock for 0 Days on average.
| FEPI | OGN | |
|---|---|---|
Market Cap | $753.07M | $3.61B |
Volume | 329,956 | 1,808,049 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $13.81 |
52-Week Low | $37.98 | $5.70 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.28, showing minimal daily movement with a 0.14% gain. The ETF employs a covered call strategy on AI and mega-cap tech stocks, generating substantial weekly dividends averaging $0.20-0.21 per share. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. Recent news highlights FEPI's 25% yield but notes underperformance compared to peers in total returns.
FEPI offers high income potential through its covered call strategy but faces capped upside and concentrated tech exposure risks. The ETF's performance depends heavily on AI sector volatility and options pricing efficiency. While attractive for income-focused investors, total return potential may lag broader market indices during strong bull markets.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
